NCT03811457View on ClinicalTrials.gov

Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Lymphoma Leukemia
Interventions
GENETIC

Welgenaleucel

Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.

Trial Locations (1)

252000

Liaocheng People Hospital, Liaocheng

All Listed Sponsors
collaborator

Liaocheng People's Hospital

OTHER

lead

UWELL Biopharma

INDUSTRY

NCT03811457 - Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | Biotech Hunter | Biotech Hunter